EUnetHTA Joint Action 3 (2016-20) JA3-WP4
2017 - PDF

Final Project Plan for pharma JA on Regorafenib (Stivarga©)

This is the final project plan of the pharma JA on Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.